170 related articles for article (PubMed ID: 7319736)
1. Hydroxyproline and zinc excretion in patients with neoplastic breast disease.
Percudani M; Dell'Anna B; De Lorenzis GF; Ferraccioli GF; Vaona GL
Int Surg; 1981; 66(3):233-6. PubMed ID: 7319736
[TBL] [Abstract][Full Text] [Related]
2. [Hydroxyprolinuria in relation to bone metastases in patients with breast cancer].
Rico Lenza H; Millán Núñez-Cortés J; Rodríguez Mora VI; Espinós Pérez D
Rev Esp Oncol; 1980; 27(1):61-6. PubMed ID: 7209108
[TBL] [Abstract][Full Text] [Related]
3. Postabsorptive urinary hydroxyproline test in patients with metastatic bone disease from breast cancer.
Niell HB; Palmieri GM; Neely CL; McDonald MW
Arch Intern Med; 1981 Oct; 141(11):1471-3. PubMed ID: 7283558
[TBL] [Abstract][Full Text] [Related]
4. [Urinary hydroxyproline excretion before and after hypophysectomy in patients with bone metastases from breast cancer].
Ditzel J; Jordal R; Riskoer N
Ugeskr Laeger; 1968 Oct; 130(42):1766-71. PubMed ID: 5724711
[No Abstract] [Full Text] [Related]
5. [Hydroxyproline in the diagnosis of bone metastases in breast cancer].
Gasser AB; Depierre D; Alberto P; Courvoisier B
Schweiz Med Wochenschr; 1977 Jul; 107(28):984-6. PubMed ID: 897640
[TBL] [Abstract][Full Text] [Related]
6. [Urinary hydroxyproline in advanced breast carcinoma and response to treatment with medroxyprogesterone acetate (MAP) in high doses].
Martoni A; Pedelini G; Colalongo G; Biagi R; Mambelli M; Jafelice G; Rocchetta G; Piana E; Pannuti F
Minerva Med; 1980 Sep; 71(31):2215-9. PubMed ID: 7422143
[TBL] [Abstract][Full Text] [Related]
7. Hydroxyproline excretion in malignant neoplastic disease.
Hosley HF; Taft EG; Olson KB; Gates S; Beebe RT
Arch Intern Med; 1966 Dec; 118(6):565-71. PubMed ID: 5925444
[No Abstract] [Full Text] [Related]
8. 'Early' breast cancer, bone scanning, and the urinary excretion of hydroxyproline.
Sumner DS; Baum M; Parsons V; Edwards MH
Br J Surg; 1973 Apr; 60(4):306. PubMed ID: 4700234
[No Abstract] [Full Text] [Related]
9. [Variable behavior of urinary hydroxyproline in breast cancer with osseous metastases].
Polico C; Nascimben O; Maccari F; Fazzin G
Quad Sclavo Diagn; 1978 Dec; 14(4):486-93. PubMed ID: 757622
[TBL] [Abstract][Full Text] [Related]
10. Relevance of hydroxyproline excretion to bone metastasis in breast cancer.
Gielen F; Dequeker J; Drochmans A; Wildiers J; Merlevede M
Br J Cancer; 1976 Sep; 34(3):279-85. PubMed ID: 974001
[TBL] [Abstract][Full Text] [Related]
11. [Urinary hydroxyproline and cancer of the breast].
Bellido V; Carda P; Mascías E
Rev Esp Oncol; 1983; 30(1):7-16. PubMed ID: 6679910
[No Abstract] [Full Text] [Related]
12. Urinary hydroxyproline excretion in patients with breast cancer.
Cuschieri A; Felgate R
Br J Surg; 1971 Nov; 58(11):862. PubMed ID: 5124876
[No Abstract] [Full Text] [Related]
13. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
[TBL] [Abstract][Full Text] [Related]
14. [Use of urinary hydroxyproline excretion as a marker of bone metastases in prostatic cancer (1)].
Kurokawa K; Imai K; Yamanaka H; Tomaru Y; Kitaura K
Hinyokika Kiyo; 1985 Dec; 31(12):2119-25. PubMed ID: 2421558
[TBL] [Abstract][Full Text] [Related]
15. [Hydroxyproline excretion as an index for the evaluation of metabolic bone changes].
Mühlbach R
Beitr Orthop Traumatol; 1966 Oct; 13(10):606-8. PubMed ID: 5977397
[No Abstract] [Full Text] [Related]
16. Total, dialyzable, and nondialyzable postabsorptive hydroxyproline. Values in patients with cancer.
Niell HB; Palmieri GM; Neely CL; Maxwell TA; Hopkins SC; Soloway MS
Arch Intern Med; 1983 Oct; 143(10):1925-7. PubMed ID: 6625779
[TBL] [Abstract][Full Text] [Related]
17. Biochemical picture of bone metabolism in breast cancer patients with bone metastases.
Berruti A; Torta M; Piovesan A; Raucci CA; Orlandi F; Panero A; Dogliotti L; Angeli A
Anticancer Res; 1995; 15(6B):2871-5. PubMed ID: 8669881
[TBL] [Abstract][Full Text] [Related]
18. Urinary excretion of deoxypyridinoline in patients with breast cancer.
Nguyen-Pamart M; Bonneterre J; Hecquet B
Anticancer Res; 1995; 15(4):1601-3. PubMed ID: 7654055
[TBL] [Abstract][Full Text] [Related]
19. Renal tubular dysfunction and urinary zinc excretion in breast cancer patients treated with anthracycline-based combination chemotherapy.
Králícková P; Melichar B; Malír F; Roubal T
J Exp Clin Cancer Res; 2004 Dec; 23(4):579-84. PubMed ID: 15743027
[TBL] [Abstract][Full Text] [Related]
20. Urinary hydroxyproline and prognosis in human breast cancer.
Grant CS; Hoare SA; Millis RR; Hayward JL; Wang DY
Br J Surg; 1984 Feb; 71(2):105-8. PubMed ID: 6692099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
